2nd Quarter - Report

INTERNATIONAL MYELOMA FOUNDATION for INTERNATIONAL MYELOMA FOUNDATION

Firm
Client
Income
—
Expenses
$36,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2746 Cancer Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act

LobbyistCovered position, as disclosed
ARIN ASSERO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2245 (112th), S. 2516 (112th), S. 296 (112th), H.R. 2746 (112th)

Medical/Disease Research/Clinical Labs MED

HR 2746 Cancer Drug Coverage Parity Act; HR 2245/S.296 Preserving Access to Lifesaving Medications Act; S.2516 Food and Drug Administration Safety and Innovation Act

LobbyistCovered position, as disclosed
ARIN ASSERO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2516 (112th), H.R. 2245 (112th), H.R. 2746 (112th), S. 296 (112th)

Budget/Appropriations BUD

S.3295/ (no House number posted yet), Labor HHS & Education, FY 2013 H.R. 5973/S. 2375, Agriculture, FY 2013

LobbyistCovered position, as disclosed
ARIN ASSERO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3295 (112th), H.R. 5973 (112th), S. 2375 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.